ACBM OTC
Acro Biomedical Co., Ltd.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +17.1%
1Y: +3614.3%
3Y: -99.3%
$0.03
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$154K
-305.8% ▼
Net Income
-$101K
-139.1% ▼
EPS (Diluted)
$-0.00
-142.9% ▼
EBITDA
-$154K
-305.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1M | $658K | $0 | $0 | $0 |
| YoY Growth | +74.1% | -45.0% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $938K | $518K | $0 | $0 | $0 |
| Gross Profit | $260K | $140K | $0 | $0 | $0 |
| Gross Margin | 21.7% | 21.3% | — | — | — |
| R&D Expenses | $5M | $10M | $5M | $0 | $0 |
| SG&A Expenses | $3M | $6M | $4M | $38K | $154K |
| Operating Expenses | $8M | $16M | $9M | $38K | $154K |
| Operating Income | -$8M | -$16M | -$9M | -$38K | -$154K |
| Operating Margin | -642.5% | -2410.0% | — | — | — |
| Interest Expense | $4K | $2K | $3K | $4K | $9K |
| Income Before Tax | -$8M | -$16M | -$9M | -$42K | -$101K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$8M | -$16M | -$9M | -$42K | -$101K |
| Net Margin | -643.2% | -2410.2% | — | — | — |
| EPS (Diluted) | $-0.14 | $-0.26 | $-0.15 | $-0.00 | $-0.00 |
| EBITDA | $0 | -$16M | $0 | -$38K | -$154K |
| Shares Outstanding | 54M | 60M | 60M | 60M | 60M |